Gamma Delta T Cells in AML

Acute Myeloid Leukemia Clinical Trial

Official title:

Assessing Feasibility of Expansion and Characterization of Gamma Delta T Cells From Peripheral Blood and Bone Marrow of Patients With Acute Myeloid Leukaemia as Starting Product for Generation of CD33-CD28 Gamma Delta T Cells

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03885076
• Other study ID #: CCR4877
• Status: Recruiting
• Start date: August 23, 2018
• Est. completion date: March 2021

Study information

• Verified date: June 2019
• Source: Royal Marsden NHS Foundation Trust
• Contact: Ms C McCormack
• Phone: 020 8661 3202
• Email: chloe.mccormack[@]rmh.nhs.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Royal Marsden NHS Foundation Trust is committed to improving patient experience; this research is being undertaken to try to develop a novel treatment for patients with Acute Myeloid Leukaemia (AML). Researchers aim to develop a new therapy which uses a patient's own immune cells called T cells to treat AML. In this study, numbers and properties of T cells which can be collected from the blood of patients with AML at various points throughout their treatment will be investigated. Blood samples will be collected at the same time as the patient's bone marrow test.

If patients need further bone marrow tests during their course of treatment to assess the status of disease, the research team would ask that additional samples are taken at the same time as the bone marrow and blood will be collected at the same time as the routine blood draw.

Following collection of blood samples, they will be used to purify a population of blood cells called Gamma Delta T cells which have been shown to have a potential role in control of cancers. In addition the researchers plan to determine whether it is possible to put a novel receptor called a chimeric antigen receptor (CAR) to potentially directly target leukaemia cells. Currently this is only an exploratory study and none of the samples collected will be used for treatment and is only to assess whether or not this strategy is feasible. This may however lead on to studies in the future looking at the safety and effectiveness of this strategy. This hopefully will lead in the future to improvements in treatment and outcome for patients with AML.

If patients need further bone marrow tests during their course of treatment to assess the status of disease, the research team would ask that additional samples are taken at the same time as the bone marrow and blood will be collected at the same time as the routine blood draw.

Following collection of blood samples, they will be used to purify a population of blood cells called Gamma Delta T cells which have been shown to have a potential role in control of cancers. In addition the researchers plan to determine whether it is possible to put a novel receptor called a chimeric antigen receptor (CAR) to potentially directly target leukaemia cells. Currently this is only an exploratory study and none of the samples collected will be used for treatment and is only to assess whether or not this strategy is feasible. This may however lead on to studies in the future looking at the safety and effectiveness of this strategy. This hopefully will lead in the future to improvements in treatment and outcome for patients with AML.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: March 2021
• Est. primary completion date: March 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients over the age of 18 at time of diagnosis or at time of relapse of disease

2. Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease.

3. Patients must have given informed written consent to participate in this study.

Exclusion Criteria:

1. Uncontrolled systemic infection

2. Currently receiving corticosteroids or other immune-suppressants treatment (except in cases where the patient is receiving treatment with replacement doses for adrenal insufficiency)

3. Treatment with bisphosphonates, for instance zoledronate, in the previous 3 months or throughout the trial

4. Active, known or suspected autoimmune disease such as Ulcerative Colitis / Inflammatory bowel disease, Addison's disease

5. Pregnancy or lactation before or during the study

6. Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study

7. Patients with active Hepatitis B, C or HIV will be excluded from this study

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Procedure:
• Blood collection and bone marrow aspirate
Blood and bone marrow samples will be collected for the trial alongside routine tests.

Locations

Country	Name	City	State
United Kingdom	The Royal Marsden NHS Foundation Trust	Sutton

Sponsors (2)

Lead Sponsor	Collaborator
Royal Marsden NHS Foundation Trust	TC Biopharm

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage viable gamma delta T cells	% of viable Vd2g T cells that can be generated from peripheral blood and bone marrow samples from AML patients at diagnosis and in AML patients with relapsed/refractory disease	6 months
Secondary	Transduced cells	% of Vd2g T cells transduced with a CAR.	6 months
Secondary	Target AML cells killed	% of target AML cells killed by Gamma Delta CAR-T cells	6 months
Secondary	Target monocytes killed	% of target monocytes killed by Gamma Delta Car T cells	6 months